"Submitting the NDA on schedule is an important milestone that reflects the hard work and dedication of our team and partners," said Dr. Cindy Jacobs, President and Chief Medical Officer of Achieve Life Sciences. "Cytisinicline is supported by a comprehensive clinical data package, and we're committed to working closely with the FDA to advance this important potential treatment option for adults seeking to overcome nicotine dependence." • Submitted a New Drug Application (NDA) to the U.S. Food and Drug Admi ...

Executive Summary & Financial Highlights Warner Music Group reported strong Q3 FY2025 results driven by revenue growth in recorded music and music publishing, despite a net loss, with strategic investments and efficiency initiatives supporting adjusted OIBDA expansion [Q3 FY2025 Performance Overview](index=1&type=section&id=Q3%20FY2025%20Performance%20Overview) Warner Music Group's CEO and CFO highlighted strong Q3 FY2025 performance, driven by hit songs, market share growth, and strategic investments in artists, songwriters, and technology, while focusing on efficiency and profit expansion - CEO Robert Kyncl emphasized strong revenue growth and market share gains, attributing success to strategic focus on artists, songwriters, and global impact[3](index=3&type=chunk) - CFO Armin Zerza noted robust performance reflects commitment to investing in music, enhancing efficiency, and accelerating core business growth while expanding margins[3](index=3&type=chunk) [Key Financial Highlights](index=1&type=section&id=Key%20Financial%20Highlights) The company reported accelerated revenue growth in recorded music and music publishing, supporting double-digit adjusted OIBDA growth and margin expansion, despite a net loss this quarter - Revenue re-accelerated in recorded music and music publishing, driving **double-digit adjusted OIBDA growth** and margin expansion[4](index=4&type=chunk) - Recorded music streaming performance benefited from **strong US market share growth** and chart success across geographies and genres[4](index=4&type=chunk) - Recent restructuring and catalog acquisition joint venture are expected to provide **additional capital for reinvestment**[4](index=4&type=chunk) Q3 FY2025 Key Financial Highlights | Metric | Q3 2025 ($M) | Q3 2024 ($M) | Percentage Change | | :--------------------------------- | :------ | :------ | :------- | | Total Revenue | $1,689 | $1,554 | 9% | | Net (Loss) Income | $(16) | $141 | —% (Loss) | | Operating Income | $169 | $207 | -18% | | Adjusted OIBDA | $373 | $316 | 18% | | Cash Flow from Operations | $46 | $188 | -76% | Consolidated Financial Performance Warner Music Group's Q3 FY2025 results show overall revenue growth driven by segment performance, but operating income and net income were impacted by increased expenses and foreign exchange effects [Total WMG Summary Results](index=2&type=section&id=Total%20WMG%20Summary%20Results) Warner Music Group's total revenue grew **9% to $1.689 billion** in Q3 FY2025, driven by recorded music and music publishing, though operating income declined **18%** and a **$16 million net loss** was recorded due to restructuring and foreign exchange impacts, while adjusted OIBDA increased **18%** reflecting operational efficiencies Total WMG Summary Results (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Revenue | $1,689 | $1,554 | 9 % | | Recorded Music Revenue | $1,354 | $1,251 | 8 % | | Music Publishing Revenue | $336 | $305 | 10 % | | Operating Income | $169 | $207 | -18 % | | Adjusted OIBDA | $373 | $316 | 18 % | | Net (Loss) Income | $(16) | $141 | — % | | Cash Flow from Operations | $46 | $188 | -76 % | | Free Cash Flow | $7 | $160 | -96 % | - Total revenue increased **8.7%** (**7.0% at constant currency**), with digital revenue growing **5.3%** (**4.1% at constant currency**) primarily driven by **4.0% streaming revenue growth** (**2.9% at constant currency**); excluding specific items, total revenue grew **10.2%** (**8.5% at constant currency**)[6](index=6&type=chunk) - Operating income decreased **18.4% to $169 million**, primarily due to a **$68 million increase in restructuring and impairment charges**, **$12 million higher amortization expense**, and increased non-cash equity-based compensation and executive transition costs[7](index=7&type=chunk) - Adjusted OIBDA increased **18.0% to $373 million**, with adjusted OIBDA margin expanding **1.8 percentage points to 22.1%**, driven by revenue mix, acquisition impact, and cost savings from the 2024 strategic restructuring plan, partially offset by reinvestment in technology[8](index=8&type=chunk) [Net Loss and EPS](index=2&type=section&id=Net%20Loss%20and%20EPS) The company reported a **$16 million net loss** in Q3 FY2025, a significant decline from **$141 million net income** in the prior year, primarily due to negative foreign exchange impacts on Euro-denominated debt and hedging losses, partially offset by reduced income tax expense Net (Loss) Income and EPS (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Net (Loss) Income | $(16) | $141 | — % | | Basic and Diluted EPS for Class A and B Common Stock | $(0.03) | $0.27 | — % | - Net loss primarily resulted from a **$70 million loss** on foreign exchange rates for Euro-denominated debt (compared to a **$7 million gain** in the prior year) and **$8 million in realized and unrealized losses** from hedging activities (compared to a **$1 million gain** in the prior year)[9](index=9&type=chunk) - Net loss was partially offset by a **$25 million decrease in income tax expense**, mainly due to a pre-tax loss this quarter[9](index=9&type=chunk) [Liquidity and Cash Flow](index=3&type=section&id=Liquidity%20and%20Cash%20Flow) Warner Music Group's cash flow from operations significantly decreased **76% to $46 million**, and free cash flow dropped **96% to $7 million**, primarily due to increased A&R spending, working capital changes, and higher capital expenditures for technology investments, with a cash balance of **$527 million** and total debt of **$4.363 billion** as of June 30, 2025 Cash and Debt Position (As of June 30, 2025) | Metric | Amount ($M) | | :--------------------------------- | :---------------- | | Cash Balance | $527 | | Total Debt | $4,363 | | Net Debt | $3,836 | Cash Flow Summary (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Cash Flow from Operations | $46 | $188 | -76 % | | Free Cash Flow | $7 | $160 | -96 % | | Capital Expenditures | $39 | $28 | 39 % | - Cash flow from operations decreased primarily due to **increased A&R spending** and other changes in working capital[12](index=12&type=chunk) - Free cash flow decline also attributed to a **39% increase in capital expenditures to $39 million**, mainly for technology investments[12](index=12&type=chunk) Segment Performance The company's segment performance highlights revenue growth in both recorded music and music publishing, with adjusted OIBDA expansion, despite varying impacts on operating income due to restructuring and amortization [Recorded Music](index=4&type=section&id=Recorded%20Music) Recorded Music revenue grew **8% to $1.354 billion**, driven by digital, artist services, expanded rights, and licensing income, despite a slight decline in physical revenue, while adjusted OIBDA increased **14% to $321 million** with margin expansion due to cost savings and revenue mix, though operating income decreased due to higher restructuring and impairment charges [Recorded Music Revenue](index=4&type=section&id=Recorded%20Music%20Revenue) Recorded Music revenue increased, primarily driven by digital, artist services, and licensing, with strong streaming performance and chart success, partially offset by a slight decline in physical revenue Recorded Music Revenue (Three Months Ended June 30) | Revenue Type | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Total Recorded Music Revenue | $1,354 | $1,251 | 8 % | | Digital | $929 | $882 | 5 % | | Physical | $119 | $120 | -0.8 % | | Artist Services and Expanded Rights | $195 | $159 | 22.6 % | | Licensing | $111 | $90 | 23.3 % | - Digital revenue grew **5.3%** (**4.1% at constant currency**), with streaming revenue up **3.7%** (**2.6% at constant currency**), and subscription revenue increasing **5.3%** (**4.2% at constant currency**) due to positive market share trends and chart performance[15](index=15&type=chunk) - Licensing revenue increased **23.3%** (**19.4% at constant currency**) driven by UK and China licensing deals and the timing of other copyright infringement settlements[15](index=15&type=chunk) - Artist services and expanded rights revenue grew **22.6%** (**19.6% at constant currency**) primarily due to increased concert promotion revenue in France and Spain[15](index=15&type=chunk) - Physical revenue decreased **0.8%** (**4.0% at constant currency**), with growth from strong releases in Korea and Japan offset by a **$10 million impact** from the BMG termination agreement; excluding this, physical revenue grew **8.2%** (**4.4% at constant currency**)[15](index=15&type=chunk) - Top-selling artists this quarter included **BAEKHYUN, ROSÉ, Bruno Mars, Grateful Dead, and Teddy Swims**[15](index=15&type=chunk) [Recorded Music Operating Income & Adjusted OIBDA](index=4&type=section&id=Recorded%20Music%20Operating%20Income%20%26%20Adjusted%20OIBDA) Recorded Music operating income declined due to increased restructuring and amortization, while adjusted OIBDA grew with margin expansion, driven by strategic cost savings and revenue mix Recorded Music Operating Income and Adjusted OIBDA (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Operating Income | $201 | $230 | -13 % | | Operating Margin | 14.8 % | 18.4 % | -3.6 ppts | | Adjusted OIBDA | $321 | $281 | 14 % | | Adjusted OIBDA Margin | 23.7 % | 22.5 % | +1.2 ppts | - Operating income decreased **12.6%**, primarily due to a **$67 million increase in restructuring and impairment charges** (including long-lived asset impairment related to non-core e-commerce business) and a **$3 million increase in amortization expense** from music-related asset acquisitions[16](index=16&type=chunk)[17](index=17&type=chunk) - Adjusted OIBDA increased **14.2%** (**12.2% at constant currency**), with adjusted OIBDA margin improving **1.2 percentage points**, driven by savings from the 2024 strategic restructuring plan, partially offset by reinvestment in the business and revenue mix[18](index=18&type=chunk) [Music Publishing](index=6&type=section&id=Music%20Publishing) Music Publishing revenue grew **10% to $336 million**, driven by digital, performance, synchronization, and mechanical revenue streams, with operating income increasing **13% to $60 million** and adjusted OIBDA growing **22% to $96 million**, expanding margins primarily due to revenue mix and acquisition impacts [Music Publishing Revenue](index=6&type=section&id=Music%20Publishing%20Revenue) Music Publishing revenue increased across all streams, notably digital, performance, and synchronization, benefiting from digital deal renewals, European live events, and copyright settlements Music Publishing Revenue (Three Months Ended June 30) | Revenue Type | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Total Music Publishing Revenue | $336 | $305 | 10 % | | Performance | $58 | $52 | 11.5 % | | Digital | $204 | $194 | 5.2 % | | Mechanical | $16 | $13 | 23.1 % | | Synchronization | $54 | $42 | 28.6 % | - Digital revenue grew **5.2%** (**4.6% at constant currency**), with streaming revenue up **5.2%** (**4.1% at constant currency**), primarily influenced by digital deal renewals, mainly in the US[21](index=21&type=chunk) - Performance revenue increased **11.5%** (**9.4% at constant currency**) due to growth in concerts, radio, and live events across European territories[21](index=21&type=chunk) - Synchronization revenue grew **28.6%**, primarily due to the timing of other copyright infringement settlements, increased TV and commercial licensing activity, and a **$3 million impact** from the Tempo acquisition[21](index=21&type=chunk) [Music Publishing Operating Income & Adjusted OIBDA](index=6&type=section&id=Music%20Publishing%20Operating%20Income%20%26%20Adjusted%20OIBDA) Music Publishing operating income increased despite higher amortization, while adjusted OIBDA saw significant growth and margin expansion, driven by favorable revenue mix and acquisition impacts Music Publishing Operating Income and Adjusted OIBDA (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Operating Income | $60 | $53 | 13 % | | Operating Margin | 17.9 % | 17.4 % | +0.5 ppts | | Adjusted OIBDA | $96 | $79 | 22 % | | Adjusted OIBDA Margin | 28.6 % | 25.9 % | +2.7 ppts | - Operating income increased **13.2%**, partially offset by a **$9 million increase in amortization expense** due to acquisition impacts[22](index=22&type=chunk) - Music Publishing adjusted OIBDA grew **21.5%** (**20.0% at constant currency**), with adjusted OIBDA margin improving **2.7 percentage points**, driven by revenue mix and acquisition impacts[23](index=23&type=chunk) Recent Developments & Company Information This section covers Warner Music Group's recent dividend announcement, an overview of its global music entertainment business, and important disclosures regarding forward-looking statements and investor resources [Dividend Announcement](index=6&type=section&id=Dividend%20Announcement) Warner Music Group's Board of Directors declared a regular quarterly cash dividend of **$0.19 per share** for Class A and Class B common stock, payable on September 3, 2025 - The Board of Directors declared a regular quarterly cash dividend of **$0.19 per share** on the company's Class A and Class B common stock[24](index=24&type=chunk) - The dividend is payable on **September 3, 2025**, to stockholders of record as of the close of business on **August 20, 2025**[24](index=24&type=chunk) [About Warner Music Group](index=8&type=section&id=About%20Warner%20Music%20Group) Warner Music Group is a global music entertainment company with over **200 years of history**, encompassing iconic recorded music labels and Warner Chappell Music, a leading music publisher with a catalog of over **one million copyrighted works** - Warner Music Group, with over **200 years of history**, is a global home to creative artists, songwriters, and companies driving culture worldwide[27](index=27&type=chunk) - WMG's Recorded Music division is anchored by four iconic companies: **Atlantic, Elektra, Parlophone, and Warner Records**, complemented by renowned labels such as TenThousand Projects, 300 Entertainment, and Asylum[27](index=27&type=chunk) - Warner Chappell Music, originating from Chappell & Company founded in 1811, is one of the world's leading music publishers, boasting a catalog of over **one million copyrighted works** across various musical genres[27](index=27&type=chunk) [Forward-Looking Statements & Investor Information](index=8&type=section&id=Forward-Looking%20Statements%20%26%20Investor%20Information) This report contains forward-looking statements reflecting Warner Music Group's current views on future events and financial performance, subject to various risks and uncertainties, with investors advised to consult SEC filings for detailed risk factors and company websites for investor information and email alerts - This communication contains forward-looking statements, identified by words like "estimate," "expect," "anticipate," "plan," "intend," "believe," "forecast," or similar expressions, reflecting Warner Music Group's current views on future events and financial performance[28](index=28&type=chunk) - Forward-looking statements are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from expectations, with investors advised to refer to the company's Form 10-K, Form 10-Q, and other SEC filings for factors that could cause actual results to differ significantly[28](index=28&type=chunk) - The company maintains an investor website (www.wmg.com) as a channel for important corporate information, regularly posting financial and other material information at http://investors.wmg.com, where investors can sign up for email alerts[29](index=29&type=chunk) Supplemental Financial Information This section provides definitions and reconciliations for non-GAAP financial measures, along with detailed consolidated financial statements, segment-level performance data, and notable items impacting results [Non-GAAP Financial Measures](index=11&type=section&id=Non-GAAP%20Financial%20Measures) This section defines and explains Warner Music Group's key non-GAAP financial measures, including Adjusted OIBDA, Free Cash Flow, and Constant Currency, used to assess operating performance and liquidity as supplements to US GAAP metrics [Adjusted OIBDA Definition](index=11&type=section&id=Adjusted%20OIBDA%20Definition) Adjusted OIBDA is defined as operating income (loss) before non-cash depreciation and amortization, adjusted for non-cash equity-based compensation and other items affecting comparability - Adjusted OIBDA is defined as operating income (loss) before non-cash depreciation of tangible assets and non-cash amortization of intangible assets, further adjusted to exclude non-cash equity-based compensation and related expenses, and certain items impacting comparability, such as gains/losses on asset disposals and restructuring transformation costs[34](index=34&type=chunk) - The company considers Adjusted OIBDA an important indicator of the strength and performance of its business operations, but it should not be considered an alternative to operating income (loss) or net income (loss) reported under US GAAP[34](index=34&type=chunk) [Free Cash Flow Definition](index=17&type=section&id=Free%20Cash%20Flow%20Definition) Free Cash Flow is defined as cash flow from operating activities less capital expenditures, used to assess operational performance and available cash for various financial obligations and investments - Free Cash Flow is defined as cash flow provided by operating activities less capital expenditures[42](index=42&type=chunk) - The company uses Free Cash Flow to assess operating performance and cash available for debt repayment, working capital needs, capital expenditures, strategic acquisitions and investments, dividend payments, or debt repurchases[42](index=42&type=chunk) - Free Cash Flow is not a performance measure calculated in accordance with US GAAP and should not be considered in isolation or as a substitute for net income (loss) or cash flow from operating activities[43](index=43&type=chunk) [Constant Currency Explanation](index=15&type=section&id=Constant%20Currency%20Explanation) Constant currency information compares revenue and adjusted OIBDA by assuming consistent exchange rates across periods, aiding in understanding operational results and performance evaluation - Constant currency information compares revenue and Adjusted OIBDA by assuming exchange rates remain consistent across periods, aiding in understanding operational results and evaluating performance against prior periods[38](index=38&type=chunk) - Constant currency is calculated by applying the current year's foreign exchange rates to the prior year's revenue and Adjusted OIBDA[38](index=38&type=chunk) - Revenue and Adjusted OIBDA at constant currency are supplemental non-GAAP measures and should not be considered alternatives to revenue and Adjusted OIBDA reported under US GAAP[38](index=38&type=chunk) [Detailed Financial Statements and Reconciliations](index=8&type=section&id=Detailed%20Financial%20Statements%20and%20Reconciliations) This section provides comprehensive financial tables, including condensed consolidated statements of operations, balance sheets, cash flows, digital revenue breakdown, detailed reconciliations for non-GAAP measures like Adjusted OIBDA and Free Cash Flow, and revenue and OIBDA by geography and segment, along with notable items impacting performance [Condensed Consolidated Statements of Operations](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This table presents the condensed consolidated statements of operations, detailing revenue, costs, operating income, and net income (loss) for the three months ended June 30, 2025 and 2024 Condensed Consolidated Statements of Operations (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Revenue | $1,689 | $1,554 | 9 % | | Total Costs and Expenses | $(1,520) | $(1,348) | 13 % | | Operating Income | $169 | $207 | -18 % | | Net (Loss) Income | $(16) | $141 | — % | | Net (Loss) Income Attributable to Warner Music Group Corp | $(16) | $139 | — % | | Class A – Basic and Diluted EPS | $(0.03) | $0.27 | | | Class B – Basic and Diluted EPS | $(0.03) | $0.27 | | [Condensed Consolidated Balance Sheets](index=10&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This table provides the condensed consolidated balance sheets, outlining assets, liabilities, and equity as of June 30, 2025, compared to September 30, 2024 Condensed Consolidated Balance Sheets (As of June 30, 2025 vs. September 30, 2024) | Metric | June 30, 2025 ($M) | September 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Cash and Equivalents | $527 | $694 | -24 % | | Total Current Assets | $2,678 | $2,643 | 1 % | | Total Assets | $9,777 | $9,155 | 7 % | | Total Current Liabilities | $4,050 | $3,897 | 4 % | | Total Liabilities | $8,965 | $8,480 | 6 % | | Total Equity | $812 | $675 | 20 % | | Total Liabilities and Equity | $9,777 | $9,155 | 7 % | [Summarized Statements of Cash Flows](index=11&type=section&id=Summarized%20Statements%20of%20Cash%20Flows) This table summarizes cash flows from operating, investing, and financing activities, showing the net change in cash and equivalents for the three months ended June 30, 2025 and 2024 Summarized Statements of Cash Flows (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | | :--------------------------------- | :------------ | :------------ | | Cash Flow from Operations | $46 | $188 | | Cash Flow Used in Investing Activities | $(71) | $(76) | | Cash Flow Used in Financing Activities | $(96) | $(90) | | Net (Decrease) Increase in Cash and Equivalents | $(110) | $20 | [Digital Revenue Summary](index=11&type=section&id=Digital%20Revenue%20Summary) This table provides a summary of digital revenue by segment and type, including streaming, downloads, and other digital income, for the three months ended June 30, 2025 and 2024 Digital Revenue Summary (Three Months Ended June 30) | Segment/Type | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Recorded Music Streaming | $895 | $863 | 4 % | | Recorded Music Downloads and Other Digital | $34 | $19 | 79 % | | Total Recorded Music Digital Revenue | $929 | $882 | 5 % | | Music Publishing Streaming | $202 | $192 | 5 % | | Total Music Publishing Digital Revenue | $204 | $194 | 5 % | | Consolidated Streaming | $1,097 | $1,055 | 4 % | | Total Digital Revenue | $1,132 | $1,075 | 5 % | [Reconciliation of Net Income to Adjusted OIBDA](index=12&type=section&id=Reconciliation%20of%20Net%20Income%20to%20Adjusted%20OIBDA) This table reconciles net income (loss) to adjusted OIBDA, detailing adjustments for amortization, depreciation, restructuring, impairment, and non-cash equity-based compensation for the three months ended June 30, 2025 and 2024 Reconciliation of Net Income to Adjusted OIBDA (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Net (Loss) Income | $(16) | $141 | — % | | Operating Income | $169 | $207 | -18 % | | Amortization Expense | $67 | $55 | 22 % | | Depreciation Expense | $29 | $25 | 16 % | | Restructuring and Impairment | $69 | $1 | — % | | Non-Cash Equity-Based Compensation and Other Related Costs | $16 | $11 | 45 % | | Adjusted OIBDA | $373 | $316 | 18 % | [Reconciliation of Segment Operating Income to Adjusted OIBDA](index=13&type=section&id=Reconciliation%20of%20Segment%20Operating%20Income%20to%20Adjusted%20OIBDA) This section provides detailed reconciliations of operating income to adjusted OIBDA for WMG total, Recorded Music, and Music Publishing segments, including adjustments for depreciation, amortization, restructuring, and non-cash equity compensation Total WMG Adjusted OIBDA Reconciliation (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Total WMG Operating Income – GAAP | $169 | $207 | -18 % | | Depreciation and Amortization Expense | $96 | $80 | 20 % | | Restructuring and Impairment | $69 | $1 | — % | | Non-Cash Equity-Based Compensation and Other Related Costs | $16 | $11 | 45 % | | Total WMG Adjusted OIBDA | $373 | $316 | 18 % | Recorded Music Adjusted OIBDA Reconciliation (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Recorded Music Operating Income – GAAP | $201 | $230 | -13 % | | Depreciation and Amortization Expense | $47 | $43 | 9 % | | Restructuring and Impairment | $69 | $0 | — % | | Non-Cash Equity-Based Compensation and Other Related Costs | $4 | $6 | -33 % | | Recorded Music Adjusted OIBDA | $321 | $281 | 14 % | Music Publishing Adjusted OIBDA Reconciliation (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | Percentage Change | | :--------------------------------- | :------------ | :------------ | :------- | | Music Publishing Operating Income – GAAP | $60 | $53 | 13 % | | Depreciation and Amortization Expense | $35 | $25 | 40 % | | Non-Cash Equity-Based Compensation and Other Related Costs | $1 | $1 | — % | | Music Publishing Adjusted OIBDA | $96 | $79 | 22 % | [Revenue by Geography and Segment](index=15&type=section&id=Revenue%20by%20Geography%20and%20Segment) This section presents revenue breakdowns by geographic region (US and International) and by business segment (Recorded Music and Music Publishing), both at constant currency, for the three months ended June 30, 2025 and 2024 Revenue by Geography (Three Months Ended June 30, Constant Currency) | Geographic Region | June 30, 2025 ($M) | June 30, 2024 (Constant Currency, $M) | Percentage Change (Constant Currency) | | :--------------------------------- | :------------ | :-------------------- | :------------------ | | US Recorded Music | $536 | $517 | 4 % | | US Music Publishing | $186 | $161 | 16 % | | International Recorded Music | $818 | $755 | 8 % | | International Music Publishing | $150 | $146 | 3 % | | Total Revenue | $1,689 | $1,578 | 7 % | Revenue by Segment (Three Months Ended June 30, Constant Currency) | Segment | June 30, 2025 ($M) | June 30, 2024 (Constant Currency, $M) | Percentage Change (Constant Currency) | | :--------------------------------- | :------------ | :-------------------- | :------------------ | | Recorded Music | $1,354 | $1,272 | 6 % | | Music Publishing | $336 | $307 | 9 % | | Total Revenue | $1,689 | $1,578 | 7 % | [Adjusted OIBDA by Segment](index=16&type=section&id=Adjusted%20OIBDA%20by%20Segment) This table presents adjusted OIBDA by segment for WMG total, Recorded Music, and Music Publishing, at constant currency, for the three months ended June 30, 2025 and 2024 Adjusted OIBDA by Segment (Three Months Ended June 30, Constant Currency) | Segment | June 30, 2025 ($M) | June 30, 2024 (Constant Currency, $M) | Percentage Change (Constant Currency) | | :--------------------------------- | :------------ | :-------------------- | :------------------ | | Total WMG Adjusted OIBDA | $373 | $322 | 15.8 % | | Recorded Music Adjusted OIBDA | $321 | $286 | 12.2 % | | Music Publishing Adjusted OIBDA | $96 | $80 | 20.0 % | [Notable Items](index=17&type=section&id=Notable%20Items) This section highlights specific items that significantly impacted revenue and adjusted OIBDA for Recorded Music in Q3 FY2025, including copyright settlements and the BMG termination agreement Notable Items Impacting Revenue (Q3 FY2025) | Item | Impact on Recorded Music Revenue (Q3 2025, $M) | | :--------------------------------- | :--------------------------------- | | Downloads and Other Digital - Copyright Settlement | $16 | Notable Items Impacting Adjusted OIBDA (Q3 FY2025) | Item | Impact on Recorded Music Adjusted OIBDA (Q3 2025, $M) | | :--------------------------------- | :--------------------------------- | | Copyright Settlement | $9 | - The BMG termination agreement negatively impacted Recorded Music revenue by **$14 million** compared to the prior year (comprising **$10 million in physical revenue** and **$4 million in streaming revenue**)[6](index=6&type=chunk)[15](index=15&type=chunk) - The prior year included **$22 million in incremental Recorded Music streaming revenue** from digital service providers (DSP make-whole payments), affecting year-over-year comparison[6](index=6&type=chunk)[15](index=15&type=chunk) [Calculation of Free Cash Flow](index=18&type=section&id=Calculation%20of%20Free%20Cash%20Flow) This table details the calculation of free cash flow by subtracting capital expenditures from cash flow from operating activities for the three months ended June 30, 2025 and 2024 Calculation of Free Cash Flow (Three Months Ended June 30) | Metric | June 30, 2025 ($M) | June 30, 2024 ($M) | | :--------------------------------- | :------------ | :------------ | | Cash Flow from Operations | $46 | $188 | | Less: Capital Expenditures | $39 | $28 | | Free Cash Flow | $7 | $160 |

Exhibit 99.1 PRESS RELEASE Ingles Markets, Inc. Contact: Pat Jackson, Chief Financial Officer pjackson@ingles-markets.com (828) 669-2941 (Ext. 223) ASHEVILLE, N.C. - Ingles Markets, Incorporated (NASDAQ: IMKTA) today reported results for the three and nine months ended June 28, 2025. August 7, 2025 For Immediate Release Ingles Markets, Incorporated Reports Results for Third Quarter and First Nine Months of Fiscal 2025 Robert P. Ingle II, Chairman of the Board, stated, "We appreciate our associates as they c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR (Exact name of registrant as specified in its charter) Virginia (State or other jurisdiction of incorporation or organization) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

[Executive Summary](index=1&type=section&id=Executive%20Summary) Silence Therapeutics reported positive Phase 1 data for divesiran in Polycythemia Vera, with the SANRECO Phase 2 trial on track, and maintained a strong financial position with $114.2 million in cash, extending its runway into 2028 [Q2 2025 Business and Strategic Highlights](index=1&type=section&id=Q2%202025%20Business%20and%20Strategic%20Highlights) The second quarter of 2025 was marked by positive updated Phase 1 data for divesiran in Polycythemia Vera, reinforcing its therapeutic potential. The SANRECO Phase 2 trial remains a top priority, progressing towards full enrollment by year-end 2025 - Presented updated SANRECO Phase 1 data at EHA 2025, further supporting divesiran's potential as a first-in-class siRNA in PV[1](index=1&type=chunk)[2](index=2&type=chunk) - The SANRECO Phase 2 study for divesiran is on-track for complete enrollment by year-end 2025 and remains the company's top priority[1](index=1&type=chunk)[2](index=2&type=chunk) [Q2 2025 Financial Overview](index=1&type=section&id=Q2%202025%20Financial%20Overview) Silence Therapeutics maintained a strong financial position, ending Q2 2025 with approximately $114.2 million in cash and cash equivalents and short-term investments, which is expected to fund operational plans into 2028 | Metric | Value (as of June 30, 2025) | | :----- | :-------------------------- | | Cash and cash equivalents and short-term investments | $114.2 million | | Cash runway guidance | Into 2028 | [Business and R&D Updates](index=1&type=section&id=Second%20Quarter%202025%20%26%20Recent%20Business%20Highlights) The company advanced divesiran for Polycythemia Vera with positive Phase 1 data and ongoing Phase 2 enrollment, completed Phase 3 readiness for zerlasiran, and prioritized extra-hepatic siRNA targeting while pausing SLN548 development [Divesiran for Polycythemia Vera (PV)](index=1&type=section&id=Divesiran%20for%20Polycythemia%20Vera%20%28PV%29) Divesiran continues to show compelling therapeutic potential for Polycythemia Vera, with updated Phase 1 data demonstrating durable hematocrit control and improved iron deficiency. The Phase 2 SANRECO trial is progressing well, exceeding 50% enrollment and remaining on track for year-end completion - Divesiran is being developed as a first-in-class siRNA for Polycythemia Vera (PV)[2](index=2&type=chunk)[3](index=3&type=chunk) - The SANRECO Phase 2 trial for divesiran in PV patients is a top priority and continues to progress towards full enrollment this year[2](index=2&type=chunk)[6](index=6&type=chunk) [SANRECO Phase 1 Data Presentation](index=1&type=section&id=SANRECO%20Phase%201%20Data%20Presentation) Updated Phase 1 data for divesiran demonstrated durable hematocrit control, reduced phlebotomy needs, and improved iron deficiency, with good tolerability - Divesiran treatment led to durable hematocrit control (<45%) and essentially eliminated the need for phlebotomies in the targeted population[6](index=6&type=chunk) - Divesiran increased hepcidin and ferritin, resulting in elevation of iron body content and improved iron deficiency[6](index=6&type=chunk) - Divesiran was well tolerated with no dose-limiting toxicities[6](index=6&type=chunk) [SANRECO Phase 2 Study Progress](index=1&type=section&id=SANRECO%20Phase%202%20Study%20Progress) The SANRECO Phase 2 trial has exceeded 50% enrollment and remains on schedule for completion by year-end 2025 - Exceeded **50% enrollment** in the Phase 2 portion of the SANRECO trial[6](index=6&type=chunk) - Remains on-track to complete enrollment by year-end 2025[6](index=6&type=chunk) [Zerlasiran for Cardiovascular Disease](index=1&type=section&id=Zerlasiran%20for%20Cardiovascular%20Disease) Silence Therapeutics has completed core Phase 3 readiness activities for zerlasiran, including manufacturing and supply scale-up, and is actively seeking third-party partners for its Phase 3 development and potential commercialization - Completed core Phase 3 readiness activities for zerlasiran, including manufacturing and supply scale up[4](index=4&type=chunk) - Actively in dialogues with potential third-party partners for Phase 3 development of zerlasiran as well as potential future commercialization activities[4](index=4&type=chunk) [Other Research & Development Activities](index=1&type=section&id=Other%20R%26D%20Updates) The company is prioritizing extra-hepatic cell targeting of siRNA due to promising initial preclinical activity in mice models, leading to the decision to pause the initiation of a Phase 1 study for SLN548, an siRNA for complement-mediated diseases - Prioritizing extra-hepatic activities due to promising initial preclinical activity in mice models for extra-hepatic cell targeting of siRNA[5](index=5&type=chunk) - Decided to pause initiating a Phase 1 study of SLN548, a wholly owned siRNA for complement-mediated diseases[5](index=5&type=chunk) [Collaborations](index=2&type=section&id=Collaborations) A Phase 1 study for SLN312, a siRNA product candidate licensed to AstraZeneca, is currently ongoing, indicating continued progress in external partnerships - A Phase 1 study of our siRNA product candidate, SLN312, which is licensed to AstraZeneca, is ongoing[7](index=7&type=chunk) [Financial Performance](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Highlights) Silence Therapeutics reported an increased net loss in Q2 2025 due to higher R&D expenses and foreign currency losses, while maintaining a strong cash position with a runway into 2028 [Second Quarter 2025 Financial Highlights](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Highlights) Silence Therapeutics reported a net loss of $27.4 million for Q2 2025, an increase from $19.8 million in Q2 2024, primarily due to higher R&D expenses driven by clinical trial advancements and contract manufacturing. G&A expenses decreased due to efficiency efforts. The company ended the quarter with $114.2 million in cash and short-term investments, projecting a cash runway into 2028 | Financial Metric | Q2 2025 (in millions) | Q2 2024 (in millions) | Change (YoY) | | :--------------- | :-------------------- | :-------------------- | :----------- | | R&D Expenses | $17.6 | $13.8 | +$3.8 (+27.5%) | | G&A Expenses | $5.1 | $7.0 | -$1.9 (-27.1%) | | Net Loss | $27.4 | $19.8 | +$7.6 (+38.4%) | - The increase in R&D expenses was primarily driven by the advancement of clinical trials and an increase in contract manufacturing activities[11](index=11&type=chunk) - The decrease in G&A expenses was primarily due to a reduction in reporting and compliance requirements, as well as efforts to increase operating efficiencies[11](index=11&type=chunk) | Metric | Value (as of June 30, 2025) | | :----- | :-------------------------- | | Cash and cash equivalents, and short-term investments | $114.2 million | | Expected cash runway | Into 2028 | [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets decreased to $165.2 million from $202.6 million at December 31, 2024, primarily driven by a reduction in cash and cash equivalents. Total liabilities increased slightly, while total shareholders' equity improved from a larger deficit | Balance Sheet Item | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | Change | | :----------------- | :--------------------------- | :------------------------------- | :----- | | Total assets | $165,233 | $202,635 | -$37,402 | | Total liabilities | $(71,078) | $(68,612) | -$2,466 (increase in absolute value) | | Total shareholders' equity | $(94,155) | $(134,023) | +$39,868 (reduction in deficit) | | Cash and cash equivalents | $41,739 | $121,330 | -$79,591 | | Short-term investments | $72,416 | $26,004 | +$46,412 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the three months ended June 30, 2025, Silence Therapeutics reported a net loss of $27.4 million, an increase from $19.8 million in the prior year period. This was influenced by a significant foreign currency loss and increased R&D costs, despite a decrease in G&A expenses | Income Statement Item | Three months ended June 30, 2025 (in thousands) | Three months ended June 30, 2024 (in thousands) | Change (YoY) | | :-------------------- | :---------------------------------------------- | :---------------------------------------------- | :----------- | | Revenue | $224 | $756 | -$532 (-70.4%) | | Gross profit | $139 | $(2,577) | +$2,716 (swing to profit) | | Research and development costs | $(17,647) | $(13,802) | -$(3,845) (+27.9%) | | General and administrative expenses | $(5,131) | $(7,009) | +$1,878 (-26.8%) | | Operating loss | $(23,963) | $(23,388) | -$(575) (+2.5%) | | Foreign currency (loss)/gain, net | $(6,613) | $(222) | -$(6,391) (significant increase in loss) | | Net Loss | $(27,354) | $(19,755) | -$(7,599) (+38.5%) | | Loss per share (basic and diluted) | $(0.19) | $(0.14) | -$(0.05) (+35.7%) | - The company incurred a significant foreign currency loss of **$6.6 million** in Q2 2025, compared to a loss of **$0.2 million** in Q2 2024[17](index=17&type=chunk) [Corporate Information](index=2&type=section&id=Corporate%20Information) Silence Therapeutics is a clinical-stage biotechnology company focused on siRNA therapies for cardiovascular, hematology, and rare diseases, with forward-looking statements subject to inherent risks [About Silence Therapeutics](index=2&type=section&id=About%20Silence%20Therapeutics) Silence Therapeutics is a global clinical-stage biotechnology company dedicated to transforming lives through precision-engineered siRNA medicines. It utilizes its mRNAi GOLD™ platform to target disease-associated genes, primarily in the liver, focusing on cardiovascular, hematology, and rare diseases - Silence Therapeutics is a global clinical-stage biotechnology company focused on developing novel siRNA therapies[9](index=9&type=chunk) - The company leverages its mRNAi GOLD™ platform to create siRNAs designed to precisely target and silence disease-associated genes, primarily in the liver[9](index=9&type=chunk) - Focuses on areas of high unmet medical need, with programs advancing in cardiovascular disease, hematology, and rare diseases[9](index=9&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) The report contains forward-looking statements regarding business strategy, clinical development, therapeutic benefits, trial timelines, collaborations, value delivery, and cash runway. These statements are subject to risks and uncertainties, including operating losses, capital needs, regulatory approvals, side effects, reliance on third parties, and intellectual property, as detailed in SEC filings - The press release contains forward-looking statements regarding business strategy, clinical development activities and timelines, therapeutic benefits, trial enrollment timing, collaborations, value delivery, and anticipated cash runway[10](index=10&type=chunk) - Forward-looking statements are subject to risks and uncertainties, including net operating losses, ability to obtain capital, early stages of clinical development, regulatory approval, undesirable side effects, reliance on third-party suppliers, and intellectual property rights[10](index=10&type=chunk)[12](index=12&type=chunk) - The company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law[12](index=12&type=chunk) [Inquiries](index=3&type=section&id=Inquiries) Contact information for investor relations and corporate communications is provided for inquiries regarding Silence Therapeutics - Inquiries can be directed to Gem Hopkins, VP, IR and Corporate Communications, via email or phone[13](index=13&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission file number: 001-32395 ConocoPhillips (Exact name of registrant as specified in its charter) Delaware 01- ...

EXHIBIT 99.1 CHENIERE ENERGY PARTNERS, L.P. NEWS RELEASE Cheniere Partners Reports Second Quarter 2025 Results and Reconfirms Full Year 2025 Distribution Guidance HOUSTON--(BUSINESS WIRE)-- Cheniere Energy Partners, L.P. ("Cheniere Partners") (NYSE: CQP) today announced its financial results for second quarter 2025. HIGHLIGHTS 2025 FULL YEAR DISTRIBUTION GUIDANCE SUMMARY AND REVIEW OF FINANCIAL RESULTS | (in millions, except LNG data) | | | | Three Months Ended June 30, | | | | Six Months Ended June 30, | | ...

Houston, TX, August 6, 2025 – U.S. Physical Therapy, Inc. ("USPH" or the "Company") (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the three and six months ended June 30, 2025. FINANCIAL HIGHLIGHTS • Adjusted EBITDA (1) , a non-Generally Accepted Accounting Principles ("GAAP") measure, was $26.9 million for the three months ended June 30, 2025 ("2025 Second Quarter"), an increase of $4.7 million, or 2 ...

[Financial Performance and Outlook](index=1&type=section&id=Financial%20Performance%20and%20Outlook) Cheniere reported strong Q2 2025 financial results, updated full-year guidance positively, and detailed performance drivers, including CEO commentary on strategic achievements [Second Quarter 2025 Financial Highlights](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Highlights) Cheniere reported strong Q2 2025 financial results, with significant year-over-year growth in revenues, net income, Adjusted EBITDA, and Distributable Cash Flow Q2 & H1 2025 Financial Summary | (in billions) | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | | :--- | :--- | :--- | | **Revenues** | $4.6 | $10.1 | | **Net Income** | $1.6 | $2.0 | | **Consolidated Adjusted EBITDA** | $1.4 | $3.3 | | **Distributable Cash Flow** | $0.9 | $2.2 | [Full Year 2025 Financial Guidance](index=1&type=section&id=Full%20Year%202025%20Financial%20Guidance) The company updated its full-year 2025 financial guidance, tightening the range for Adjusted EBITDA and raising and tightening Distributable Cash Flow Revised Full Year 2025 Guidance | (in billions) | 2025 Previous | 2025 Revised | | :--- | :--- | :--- | | **Consolidated Adjusted EBITDA** | $6.5 - $7.0 | $6.6 - $7.0 | | **Distributable Cash Flow** | $4.1 - $4.6 | $4.4 - $4.8 | - The updated guidance reflects a tightening of the Consolidated Adjusted EBITDA range and an increase and tightening of the Distributable Cash Flow range[7](index=7&type=chunk) [Detailed Financial Results Review](index=3&type=section&id=Detailed%20Financial%20Results%20Review) Q2 2025 revenues increased by **43%** and net income by **85%** year-over-year, driven by derivative fair value changes and higher LNG margins Q2 & H1 2025 vs 2024 Performance | (in millions) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | % Change | | :--- | :--- | :--- | :--- | | **Revenues** | $4,641 | $3,251 | 43% | | **Net income** | $1,626 | $880 | 85% | | **Consolidated Adjusted EBITDA** | $1,416 | $1,322 | 7% | - The increase in net income for Q2 2025 was primarily due to an **$873 million** favorable variance from changes in the fair value of derivative instruments compared to Q2 2024[12](index=12&type=chunk) - The increase in Consolidated Adjusted EBITDA was mainly driven by higher total margins per MMBtu of LNG, partially offset by higher operating expenses from planned maintenance and new capacity[12](index=12&type=chunk) [CEO Commentary](index=2&type=section&id=CEO%20COMMENT) CEO Jack Fusco highlighted strong Q2 performance, including the CCL Midscale Trains 8 & 9 FID and Sabine Pass maintenance, enabling revised full-year guidance and continued growth focus - Key achievements in Q2 2025 include the positive FID on the CCL Midscale Trains 8 & 9 Project and the completion of a large-scale planned maintenance at Sabine Pass[10](index=10&type=chunk) - The company's focus for the remainder of the year includes growing its brownfield platform and bringing new capacity at Corpus Christi online ahead of schedule and on budget[10](index=10&type=chunk) [Capital Management and Liquidity](index=1&type=section&id=Capital%20Management%20and%20Liquidity) Cheniere actively managed its capital allocation in H1 2025, deploying **$2.6 billion** towards growth, debt reduction, and shareholder returns, while maintaining strong liquidity [Capital Allocation](index=1&type=section&id=Capital%20Allocation) Cheniere deployed **$2.6 billion** in H1 2025 for growth, debt repayment, and shareholder returns, including a **10%** dividend increase effective Q3 2025 - In the first six months of 2025, Cheniere deployed **$2.6 billion** towards growth, balance sheet management, and shareholder returns[6](index=6&type=chunk) - Shareholder returns in H1 2025 included repurchasing **3.0 million** shares for **$656 million** and paying dividends totaling **$223 million**[6](index=6&type=chunk) - The company announced an increase in its quarterly dividend by over **10%** to **$2.22** per common share annualized, starting in Q3 2025[11](index=11&type=chunk) [Balance Sheet and Liquidity](index=3&type=section&id=BALANCE%20SHEET%20MANAGEMENT) As of June 30, 2025, Cheniere maintained **$9.7 billion** in total available liquidity and actively managed debt through new issuances and repayments Available Liquidity as of June 30, 2025 | (in millions) | Amount | | :--- | :--- | | Cash and cash equivalents | $1,648 | | Restricted cash and cash equivalents | $369 | | Available commitments under credit facilities | $7,685 | | **Total available liquidity** | **$9,702** | - In July 2025, Cheniere Partners issued **$1.0 billion** of 5.550% Senior Notes due 2035 to redeem **$1.0 billion** of 5.875% Senior Secured Notes due 2026[16](index=16&type=chunk) - During H1 2025, SPL repaid the remaining **$300 million** of its 5.625% Senior Secured Notes due 2025 with cash on hand[17](index=17&type=chunk) [Operational and Project Updates](index=2&type=section&id=Operational%20and%20Project%20Updates) Cheniere secured new long-term commercial agreements, increased its LNG production forecast, and advanced multiple liquefaction expansion projects at Sabine Pass and Corpus Christi [Recent Commercial and Growth Highlights](index=2&type=section&id=Recent%20Commercial%20and%20Growth%20Highlights) Cheniere secured new long-term commercial agreements, increased its run-rate LNG production forecast by over **10%**, and expects to generate over **$25 billion** in available cash through 2030 - The company increased its run-rate LNG production forecast by over **10%** and expects to generate over **$25 billion** of available cash through 2030[11](index=11&type=chunk) - Entered a 15-year IPM gas supply agreement with Canadian Natural Resources for **140,000 MMBtu/day**, equivalent to approximately **0.85 mtpa** of LNG[11](index=11&type=chunk) - Signed a long-term SPA with JERA to supply approximately **1.0 mtpa** of LNG from 2029 through 2050[11](index=11&type=chunk) [Liquefaction Projects Overview](index=4&type=section&id=LIQUEFACTION%20PROJECTS%20OVERVIEW) Cheniere is advancing multiple liquefaction expansion projects at Sabine Pass and Corpus Christi, achieving key milestones including CCL Stage 3 Train 2 completion and FID for Midscale Trains 8 & 9 [Sabine Pass LNG (SPL) Projects](index=4&type=section&id=Sabine%20Pass%20LNG%20(SPL)%20Projects) The operational SPL Project has over **30 mtpa** capacity, with an expansion project under development expected to add up to **20 mtpa** in a two-phased approach - The operational SPL Project has a total production capacity of over **30 mtpa** of LNG[18](index=18&type=chunk) - The SPL Expansion Project is being developed with an expected peak production capacity of up to **~20 mtpa**. Its FERC application was updated in June 2025 to reflect a two-phased project[19](index=19&type=chunk) [Corpus Christi LNG (CCL) Projects](index=4&type=section&id=Corpus%20Christi%20LNG%20(CCL)%20Projects) The CCL Project has over **18 mtpa** operational capacity, with Stage 3 **86.7%** complete, FID for Midscale Trains 8 & 9 adding **~5 mtpa**, and Stage 4 Expansion pre-filing initiated for **~24 mtpa** - The CCL Stage 3 Project was **86.7%** complete as of June 30, 2025, with substantial completion for all seven trains expected between 2H 2025 and 2H 2026[21](index=21&type=chunk) - A positive Final Investment Decision (FID) was made in June 2025 for the CCL Midscale Trains 8 & 9 Project, which will add approximately **5 mtpa** of production capacity[11](index=11&type=chunk)[22](index=22&type=chunk)[23](index=23&type=chunk) - The pre-filing review process with FERC was initiated in July 2025 for the CCL Stage 4 Expansion Project, which has an expected peak production capacity of up to **~24 mtpa**[24](index=24&type=chunk) [LNG Volume Summary](index=6&type=section&id=LNG%20VOLUME%20SUMMARY) As of August 1, 2025, Cheniere exported approximately **4,220** cumulative LNG cargoes, with **550 TBtu** exported in Q2 2025 - As of August 1, 2025, a cumulative total of approximately **4,220** LNG cargoes, totaling **~290 million tonnes**, have been exported from Cheniere's projects[32](index=32&type=chunk) LNG Volumes Recognized (in TBtu) | | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | | :--- | :--- | :--- | | **Operational Volumes** | 550 | 1,159 | | **Commissioning Volumes** | 1 | 6 | | **Total Volumes Recognized** | 551 | 1,165 | [Financial Statements](index=7&type=section&id=Financial%20Statements) This section presents Cheniere's consolidated statements of operations and balance sheets, highlighting significant revenue growth, increased net income, and a strengthened equity position [Consolidated Statements of Operations](index=7&type=section&id=Consolidated%20Statements%20of%20Operations) Q2 2025 saw total revenues of **$4.64 billion**, income from operations more than doubled to **$2.53 billion**, and net income attributable to Cheniere reached **$1.63 billion** Q2 2025 vs Q2 2024 Statement of Operations (in millions) | | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | **Total revenues** | $4,641 | $3,251 | | **Income from operations** | $2,530 | $1,588 | | **Net income attributable to Cheniere** | $1,626 | $880 | | **Diluted EPS** | $7.30 | $3.84 | [Consolidated Balance Sheets](index=8&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets were **$44.58 billion**, total liabilities decreased to **$33.27 billion**, and total stockholders' equity increased to **$11.25 billion** Balance Sheet Summary (in millions) | | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total current assets** | $3,704 | $4,801 | | **Total assets** | $44,578 | $43,858 | | **Total current liabilities** | $3,775 | $4,441 | | **Total liabilities** | $33,269 | $33,798 | | **Total stockholders' equity** | $11,251 | $10,053 | [Reconciliation of Non-GAAP Measures](index=10&type=section&id=Reconciliation%20of%20Non-GAAP%20Measures) This section provides detailed reconciliations of non-GAAP financial measures, specifically Consolidated Adjusted EBITDA and Distributable Cash Flow, to their most directly comparable GAAP measures [Reconciliation of Consolidated Adjusted EBITDA](index=10&type=section&id=Reconciliation%20of%20Consolidated%20Adjusted%20EBITDA) Q2 2025 Consolidated Adjusted EBITDA was **$1.42 billion**, reconciled from income from operations by adjusting for depreciation and derivative fair value changes Q2 2025 Reconciliation to Consolidated Adjusted EBITDA (in millions) | | Three Months Ended June 30, 2025 | | :--- | :--- | | **Income from operations** | $2,530 | | Depreciation, amortization and accretion expense | $329 | | Gain from changes in fair value of derivatives, net | ($1,479) | | Other adjustments | $36 | | **Consolidated Adjusted EBITDA** | **$1,416** | - Consolidated Adjusted EBITDA is calculated by adjusting net income for interest, taxes, depreciation, and certain non-cash or non-operating items to assess the financial performance of assets[42](index=42&type=chunk)[44](index=44&type=chunk) [Reconciliation of Distributable Cash Flow](index=11&type=section&id=Reconciliation%20of%20Distributable%20Cash%20Flow) Q2 2025 Distributable Cash Flow was **$0.92 billion**, derived from Consolidated Adjusted EBITDA after accounting for interest, capital expenditures, taxes, and non-controlling interests Q2 2025 Reconciliation to Distributable Cash Flow (in billions) | | Three Months Ended June 30, 2025 | | :--- | :--- | | **Consolidated Adjusted EBITDA** | $1.42 | | Interest expense, net | ($0.19) | | Maintenance capital expenditures | ($0.06) | | Income tax (excludes deferred taxes) | ($0.02) | | Other | ($0.02) | | **Consolidated Distributable Cash Flow** | $1.13 | | Attributable to non-controlling interests | ($0.20) | | **Cheniere Distributable Cash Flow** | **$0.92** | - Distributable Cash Flow is a performance measure used to evaluate the ability of assets to generate cash earnings after servicing debt, paying cash taxes, and funding sustaining capital[48](index=48&type=chunk)

[PART I - FINANCIAL INFORMATION](index=11&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) Details the company's unaudited condensed consolidated financial statements and management's analysis of financial condition and operations [Financial Statements](index=11&type=section&id=ITEM%201.%20Financial%20Statements) Details unaudited condensed consolidated financial statements, highlighting asset growth, revenue decline, and reduced net income due to investment-related gains Condensed Consolidated Statements of Financial Condition (Unaudited) | (In millions) | As of June 30, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | **Total Assets** | **$419,550** | **$377,895** | | Total Asset Management Assets | $15,060 | $15,256 | | Total Retirement Services Assets | $404,490 | $362,639 | | **Total Liabilities** | **$385,689** | **$346,915** | | Total Asset Management Liabilities | $10,167 | $9,968 | | Total Retirement Services Liabilities | $375,522 | $336,947 | | **Total Equity** | **$33,861** | **$30,964** | Condensed Consolidated Statements of Operations (Unaudited) | (In millions, except per share data) | Six months ended June 30, 2025 | Six months ended June 30, 2024 | | :--- | :--- | :--- | | **Total Revenues** | **$12,362** | **$13,058** | | Asset Management Revenues | $2,153 | $2,089 | | Retirement Services Revenues | $10,209 | $10,969 | | **Total Expenses** | **$10,060** | **$9,475** | | **Net income (loss)** | **$1,780** | **$2,942** | | Net income (loss) attributable to common stockholders | $1,023 | $2,231 | | **Net income (loss) per share - Diluted** | **$1.67** | **$3.64** | Condensed Consolidated Statements of Cash Flows (Unaudited) | (In millions) | Six months ended June 30, 2025 | Six months ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $2,274 | $1,403 | | Net cash used in investing activities | $(36,517) | $(31,085) | | Net cash provided by financing activities | $32,089 | $29,976 | | Net increase (decrease) in cash | $(2,141) | $292 | [Note 1. Organization](index=21&type=section&id=Note%201.%20Organization) Describes Apollo's structure as an asset manager and retirement services provider, including the pending acquisition of Bridge Investment Group - Apollo operates as a **high-growth, global alternative asset manager** with a focus on **credit and equity strategies**, and a **retirement services provider** through its **Athene business**[34](index=34&type=chunk) - On **February 23, 2025**, Apollo agreed to acquire **Bridge Investment Group Holdings Inc.** in an **all-stock transaction**, with an expected closing in **Q3 2025**, subject to regulatory approvals[35](index=35&type=chunk) [Note 3. Investments](index=25&type=section&id=Note%203.%20Investments) Details total investments, primarily in Retirement Services, with significant growth in AFS securities and mortgage loans driving increased net investment income Total Investments by Segment (in millions) | Segment | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Asset Management | $5,885 | $6,086 | | Retirement Services | $329,599 | $291,167 | | **Total Investments** | **$335,484** | **$297,253** | Retirement Services AFS Securities Breakdown (June 30, 2025, in millions) | Asset Type | Amortized Cost | Fair Value | | :--- | :--- | :--- | | Corporate | $103,597 | $94,563 | | CLO | $30,620 | $31,388 | | ABS | $27,405 | $27,362 | | CMBS | $13,854 | $13,500 | | RMBS | $10,716 | $10,322 | | U.S. government and agencies | $10,117 | $9,023 | | **Total AFS (ex. related parties)** | **$199,637** | **$188,750** | Retirement Services Net Investment Income (in millions) | | Six months ended June 30, 2025 | Six months ended June 30, 2024 | | :--- | :--- | :--- | | AFS securities | $5,541 | $4,477 | | Mortgage loans | $2,385 | $1,704 | | **Total Net Investment Income** | **$9,117** | **$7,380** | [Note 4. Derivatives](index=35&type=section&id=Note%204.%20Derivatives) Outlines the company's use of derivatives for risk management, noting substantial notional values and significant derivative liabilities, mainly from embedded derivatives Derivative Instruments Summary (June 30, 2025, in millions) | Derivative Type | Notional Amount | Fair Value - Assets | Fair Value - Liabilities | | :--- | :--- | :--- | :--- | | **Derivatives designated as hedges** | | **$927** | **$1,316** | | Foreign currency hedges | $23,125 | $683 | $1,013 | | Interest rate swaps | $33,805 | $244 | $288 | | **Derivatives not designated as hedges** | | **$2,753** | **$15,909** | | Equity options | $91,009 | $5,069 | $146 | | Foreign currency swaps/forwards | $58,206 | $697 | $3,175 | | Embedded derivatives | N/A | $(3,221) | $12,336 | | **Total Derivatives** | | **$3,680** | **$17,225** | - Athene uses **equity indexed options** to economically hedge its **fixed indexed annuity products**, which **guarantee principal return** and **credit interest** based on market index performance[84](index=84&type=chunk) [Note 5. Variable Interest Entities](index=40&type=section&id=Note%205.%20Variable%20Interest%20Entities) Explains the consolidation of VIEs and details maximum loss exposures from unconsolidated VIEs for both Asset Management and Retirement Services segments - The assets of consolidated VIEs are **ring-fenced** and **not available to creditors** of the parent company, and investors in these VIEs have **no recourse to Apollo's assets**[95](index=95&type=chunk) Maximum Loss Exposure from Unconsolidated VIEs (in millions) | Segment | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Asset Management | $342 | $614 | | Retirement Services | $135,756 | $124,525 | [Note 6. Fair Value](index=43&type=section&id=Note%206.%20Fair%20Value) Presents the fair value hierarchy for financial assets and liabilities, with Level 2 and Level 3 assets comprising the largest portions Fair Value Hierarchy of Financial Assets (June 30, 2025, in millions) | | Level 1 | Level 2 | Level 3 | NAV | Total | | :--- | :--- | :--- | :--- | :--- | :--- | | **Asset Management** | $3,110 | $116 | $3,055 | $340 | $6,621 | | **Retirement Services** | $22,254 | $179,225 | $121,035 | $18,905 | $341,419 | | **Total Assets** | **$25,364** | **$179,341** | **$124,090** | **$19,245** | **$348,040** | Fair Value Hierarchy of Financial Liabilities (June 30, 2025, in millions) | | Level 1 | Level 2 | Level 3 | Total | | :--- | :--- | :--- | :--- | :--- | | **Asset Management** | $— | $30 | $61 | $91 | | **Retirement Services** | $10 | $4,879 | $19,468 | $24,357 | | **Total Liabilities** | **$10** | **$4,909** | **$19,529** | **$24,448** | [Note 11. Debt](index=78&type=section&id=Note%2011.%20Debt) Details total debt outstanding across segments, including recent issuances by Athene Holding Ltd. and available credit facilities Total Debt Outstanding (June 30, 2025, in millions) | Segment | Outstanding Balance | Fair Value | | :--- | :--- | :--- | | Asset Management | $4,280 | $4,308 | | Retirement Services | $7,864 | $7,507 | | **Total Debt** | **$12,144** | **$11,815** | - In Q2 2025, Athene Holding Ltd. (AHL) issued **$1.0 billion** of **6.625% Senior Notes due 2055** and **$600 million** of **6.875% Fixed-Rate Reset Junior Subordinated Debentures due 2055**[214](index=214&type=chunk)[216](index=216&type=chunk) - The company maintains several credit and liquidity facilities, including a **$1.25 billion** facility for AGM and a combined **$3.85 billion** in facilities for AHL, all of which were **undrawn** as of June 30, 2025[217](index=217&type=chunk)[219](index=219&type=chunk)[222](index=222&type=chunk)[223](index=223&type=chunk) [Note 12. Equity-Based Compensation](index=81&type=section&id=Note%2012.%20Equity-Based%20Compensation) Reports equity-based compensation expense, unrecognized RSU expense, and new RSU awards for the period Equity-Based Compensation Expense (in millions) | Period | Expense | | :--- | :--- | | Three months ended June 30, 2025 | $166 | | Three months ended June 30, 2024 | $153 | | Six months ended June 30, 2025 | $315 | | Six months ended June 30, 2024 | $342 | - As of June 30, 2025, there was **$840 million** of estimated unrecognized compensation expense related to unvested RSU awards, expected to be recognized over a weighted-average period of **2.1 years**[228](index=228&type=chunk) [Note 13. Equity](index=84&type=section&id=Note%2013.%20Equity) Outlines share repurchase activities, dividend declarations, and details on outstanding mandatory convertible preferred stock - A new share repurchase program was approved on **February 8, 2024**, authorizing up to **$3.0 billion** in common stock repurchases[242](index=242&type=chunk) - During the six months ended June 30, 2025, the company repurchased **1,392,000 shares** of common stock for **$193 million** in open market transactions[243](index=243&type=chunk) Dividends Declared per Share of Common Stock | Declaration Date | Dividend per Share | Payment Date | | :--- | :--- | :--- | | February 4, 2025 | $0.46 | February 28, 2025 | | May 2, 2025 | $0.51 | May 30, 2025 | [Note 15. Related Parties](index=90&type=section&id=Note%2015.%20Related%20Parties) Details significant transactions and balances with related parties, including investments in Athora and Atlas, and interests in strategic capital vehicles - Apollo, through ISGI, provides investment advisory services to Athora. AAM has committed up to an additional **$2.0 billion** to Athora, and Athene has committed up to an additional **$2.5 billion**, in connection with Athora's agreement to acquire a UK insurer[274](index=274&type=chunk)[283](index=283&type=chunk) - Athene has a significant investment in Atlas, an asset-backed specialty lender, holding **$4.6 billion** of AFS securities issued by Atlas or its affiliates as of June 30, 2025[284](index=284&type=chunk) - Athene's subsidiaries, ACRA 1 and ACRA 2, are partially owned by ADIP I and ADIP II, respectively, which are funds managed by Apollo. Athene's subsidiary ALRe holds a **37% economic interest** in both ACRA vehicles[291](index=291&type=chunk) [Note 16. Commitments and Contingencies](index=95&type=section&id=Note%2016.%20Commitments%20and%20Contingencies) Summarizes unfunded capital and investment commitments, contingent performance allocation obligations, and ongoing shareholder derivative litigation - Athene had commitments to make investments totaling **$33.3 billion** as of June 30, 2025, primarily for capital contributions to investment funds and mortgage loans[293](index=293&type=chunk) - The company has a contingent obligation related to performance allocations. If all existing fund investments became worthless, approximately **$5.6 billion** of cumulative revenues recognized through June 30, 2025 could be reversed[294](index=294&type=chunk) - The company is involved in a shareholder derivative complaint challenging the **$570 million** in payments made to Former Managing Partners and Contributing Partners following the merger with Athene. A Special Litigation Committee is investigating the matter, with proceedings stayed until **October 7, 2025**[313](index=313&type=chunk) [Note 17. Segments](index=101&type=section&id=Note%2017.%20Segments) Describes the company's three reportable segments and their performance, with Segment Income growing due to increased FRE and SRE - The company's three reportable segments are **Asset Management**, **Retirement Services**, and **Principal Investing**[315](index=315&type=chunk) - The key performance measure used by management is **Segment Income**, which is the sum of **Fee Related Earnings (FRE)** from Asset Management, **Spread Related Earnings (SRE)** from Retirement Services, and **Principal Investing Income (PII)**[317](index=317&type=chunk)[321](index=321&type=chunk)[322](index=322&type=chunk)[323](index=323&type=chunk) Segment Income (in millions) | | Three months ended June 30, 2025 | Three months ended June 30, 2024 | Six months ended June 30, 2025 | Six months ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Fee Related Earnings | $627 | $516 | $1,186 | $978 | | Spread Related Earnings | $821 | $710 | $1,625 | $1,527 | | Principal Investing Income | $47 | $33 | $61 | $54 | | **Segment Income** | **$1,495** | **$1,259** | **$2,872** | **$2,559** | [Unaudited Supplemental Presentation of Statements of Financial Condition](index=96&type=section&id=ITEM%201A.%20Unaudited%20Supplemental%20Presentation%20of%20Statements%20of%20Financial%20Condition) Provides a supplemental disaggregation of the consolidated balance sheet, separating Apollo's core operations from consolidated funds and VIEs Supplemental Statement of Financial Condition (June 30, 2025, in millions) | | Apollo Global Management, Inc. and Consolidated Subsidiaries | Consolidated Funds and VIEs | Eliminations | Consolidated | | :--- | :--- | :--- | :--- | :--- | | **Total Assets** | **$409,429** | **$28,240** | **$(18,119)** | **$419,550** | | **Total Liabilities** | $383,170 | $3,060 | $(541) | $385,689 | | **Total Equity** | $26,259 | $25,180 | $(17,578) | $33,861 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=100&type=section&id=ITEM%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Analyzes financial condition and results across segments, highlighting AUM growth, market conditions, and the company's strong liquidity position - As of June 30, 2025, Apollo had total AUM of **$840 billion**, with **$690 billion** in Credit and **$150 billion** in Equity strategies[339](index=339&type=chunk)[341](index=341&type=chunk)[342](index=342&type=chunk) - Management noted strong equity market performance in Q2 2025, with the S&P 500 increasing by **10.6%**. U.S. inflation was reported at **2.7%** as of June 30, 2025, and the Federal Reserve's benchmark interest rate target remained at **4.25% to 4.50%**[353](index=353&type=chunk)[354](index=354&type=chunk) - The company maintains a strong liquidity position with **$12.7 billion** of unrestricted cash and cash equivalents and **$5.1 billion** available from credit facilities as of June 30, 2025[588](index=588&type=chunk) [Results of Operations](index=129&type=section&id=Results%20of%20Operations) Summarizes consolidated results, noting decreased revenues, increased expenses, and a significant drop in net income due to investment-related swings Consolidated Results of Operations Summary (in millions) | | Six months ended June 30, 2025 | Six months ended June 30, 2024 | | :--- | :--- | :--- | | **Total Revenues** | **$12,362** | **$13,058** | | Asset Management | $2,153 | $2,089 | | Retirement Services | $10,209 | $10,969 | | **Total Expenses** | **$10,060** | **$9,475** | | **Net Income Attributable to Common Stockholders** | **$1,023** | **$2,231** | [Segment Analysis](index=142&type=section&id=Segment%20Analysis) Analyzes performance across Asset Management, Retirement Services, and Principal Investing segments, highlighting growth in FRE, SRE, and PII Segment Performance Summary (Six months ended June 30, 2025 vs 2024) | (In millions) | 2025 | 2024 | % Change | | :--- | :--- | :--- | :--- | | Fee Related Earnings (FRE) | $1,186 | $978 | 21.3% | | Spread Related Earnings (SRE) | $1,625 | $1,527 | 6.4% | | Principal Investing Income (PII) | $61 | $54 | 13.0% | [Asset Management Operating Metrics](index=144&type=section&id=Asset%20Management%20Operating%20Metrics) Presents key Asset Management operating metrics, including AUM growth, fee-generating AUM, and available 'dry powder' for investment AUM Roll-Forward (Dec 31, 2024 to June 30, 2025, in billions) | | Beginning AUM | Net Flows | Realizations | Market Activity | Ending AUM | | :--- | :--- | :--- | :--- | :--- | :--- | | **Total AUM** | **$751.0** | **$70.6** | **$(8.9)** | **$26.9** | **$839.6** | Fee-Generating AUM Roll-Forward (Dec 31, 2024 to June 30, 2025, in billions) | | Beginning FG-AUM | Net Flows | Realizations | Market Activity | Ending FG-AUM | | :--- | :--- | :--- | :--- | :--- | :--- | | **Fee-Generating AUM** | **$568.7** | **$53.7** | **$(3.6)** | **$19.6** | **$638.3** | - As of June 30, 2025, the company had **$72 billion** of 'dry powder' available for investment[525](index=525&type=chunk) [Liquidity and Capital Resources](index=166&type=section&id=Liquidity%20and%20Capital%20Resources) Assesses the company's liquidity and capital resources, detailing cash position, credit facilities, and cash flow activities - The company had **$12.7 billion** of unrestricted cash and cash equivalents and **$5.1 billion** available from credit facilities as of June 30, 2025[588](index=588&type=chunk) Cash Flow Summary (Six months ended June 30, in millions) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Operating Activities | $2,274 | $1,403 | | Investing Activities | $(36,517) | $(31,085) | | Financing Activities | $32,089 | $29,976 | [Quantitative and Qualitative Disclosures about Market Risk](index=156&type=section&id=ITEM%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) Affirms no material changes to market risk exposures, outlining primary risks for Asset Management and Retirement Services segments - There have been **no material changes** to the company's market risk exposures from those previously disclosed in the 2024 Annual Report[672](index=672&type=chunk) [Controls and Procedures](index=156&type=section&id=ITEM%204.%20Controls%20and%20Procedures) Confirms the effectiveness of disclosure controls and procedures, with no material changes to internal control over financial reporting - The CEO and CFO concluded that disclosure controls and procedures were **effective** as of the end of the period covered by the report[676](index=676&type=chunk) - **No material changes** to internal control over financial reporting occurred during the most recent quarter[677](index=677&type=chunk) [PART II - OTHER INFORMATION](index=158&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) Provides additional information on legal proceedings, risk factors, equity sales, and other miscellaneous disclosures [Legal Proceedings](index=158&type=section&id=ITEM%201.%20Legal%20Proceedings) Refers to Note 16 of the financial statements for a comprehensive summary of ongoing legal proceedings - For a summary of legal proceedings, the report incorporates by reference **Note 16** to the condensed consolidated financial statements[680](index=680&type=chunk) [Risk Factors](index=158&type=section&id=ITEM%201A.%20Risk%20Factors) Confirms no material changes to the risk factors previously disclosed in the 2024 Annual Report - There have been **no material changes** to the risk factors disclosed in the 2024 Annual Report[681](index=681&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=158&type=section&id=ITEM%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Details unregistered equity sales and share repurchase activities, including shares repurchased and remaining authorization Purchases of Equity Securities by the Issuer (Q2 2025) | Period | Total Shares Purchased | Average Price Paid per Share | Dollar Value Remaining in Program | | :--- | :--- | :--- | :--- | | April 2025 | 160 | $149.27 | $1,050,330,659 | | May 2025 | 112,051 | $139.72 | $1,034,674,472 | | June 2025 | 0 | $— | $1,034,674,472 | | **Total** | **112,211** | | | [Other Items (3, 4, 5, 6)](index=159&type=section&id=Other%20Items) Addresses non-applicable items, confirms no Rule 10b5-1 trading arrangement changes, and lists filed exhibits - Item 3 (Defaults upon Senior Securities) and Item 4 (Mine Safety Disclosures) are **not applicable**[686](index=686&type=chunk)[687](index=687&type=chunk) - **No director or officer** adopted or terminated a Rule 10b5-1 trading arrangement during the three months ended June 30, 2025[688](index=688&type=chunk)